SHZ:002393
Tianjin Lisheng Pharmaceutical Co.,Ltd. · SHZ · Healthcare · CNY · FY for 2025
Figures on this page computed 2026-11-08 13:48 UTC
Last close
n/aCNY
Market data
8.0xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
30.0%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
29.8%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
2.7%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
Follow one yuan
lens 1 of 9The five stops
5 of 5 read- After what it costs to make1,392,663,934100%
- After running the business469,957,82833.8%
- After interest and tax418,365,97530.0%
- After what it must reinvest414,394,25029.8%
- Kept after the dividend324,701,49423.3%
Of every unit of sales, 0.23 is still there after the dividend.
Of every unit of sales, 0.23 is still there after the dividend.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2025
Sales1,392,663,934
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After what it costs to make1,392,663,934
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After running the business469,957,828
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After interest and tax418,365,975
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After what it must reinvest414,394,250
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Kept after the dividend324,701,494
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY